RGEN (Repligen) Moat Score: 7/10 (As of Jun. 29, 2026)


RGEN Repligen Corp RGEN
83 GF Score
Price $146.97
GF Value $175.89
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Repligen Moat Score?

Repligen RGEN +1.14% 83 Moat Score is 7 as of Jun. 29, 2026. GuruFocus rates RGEN with a GF Score™ of 83/100 and a GF Value™ of $175.89 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 846 Medical Devices & Instruments companies, Repligen ranks better than 98.94% on this metric.

Repligen has the Moat Score of 7, which implies that the company might have Wide Moat - Entry-level wide moat, clearly possessing durable advantages.

Repligen has Wide Moat: RGEN possesses a wide moat with its proprietary technology and strong market position in bioprocessing. It benefits from significant customer switching costs, robust R&D capabilities, and a strong distribution network, providing durable competitive advantages.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Repligen might have Wide Moat - Entry-level wide moat, clearly possessing durable advantages.

Repligen  (NAS:RGEN) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Repligen Moat Score Related Terms

RGEN vs ATR, AVTR, TFX: Moat Score Comparison

For the Medical Instruments & Supplies subindustry, Repligen's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Repligen Moat Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Repligen's Moat Score distribution charts can be found below:

* The bar in red indicates where Repligen's Moat Score falls into.


RGEN
83GF Score
Repligen Corp RGEN
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 7 mean?
Repligen (RGEN) has a Moat Score of 7 as of Jun. 29, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Repligen ranks #9 out of 846 companies in the Medical Devices & Instruments industry, placing it in the top 1.1%.
Is Repligen's Moat Score too high?
Repligen's current Moat Score is 7. Based on the distribution chart, Repligen ranks #9 out of 846 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Repligen has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Repligen's Moat Score compare to ATR and AVTR?
According to the Medical Devices & Instruments industry distribution chart, Repligen ranks #9 out of 846 companies for Moat Score. This places Repligen in the top 1% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Medical Devices & Instruments company?
A good Moat Score depends on the Medical Devices & Instruments industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Repligen's current Moat Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Repligen stock overvalued right now?
Based on GuruFocus' analysis, Repligen (RGEN) is currently considered Modestly Undervalued. The stock's GF Value™ is $175.89, compared to a current price of $146.97 — trading 16.4% below its estimated fair value. The current Moat Score is 7. Repligen's overall GF Score™ is 83/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Repligen (RGEN), the current Moat Score is 7 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Repligen (RGEN) Overvalued in 2026?

Based on GuruFocus' analysis, Repligen stock appears to be undervalued. The current stock price of $146.97 is trading 16.4% below its estimated GF Value™ of $175.89. GuruFocus considers Repligen to be Modestly Undervalued.

Key valuation signals for RGEN:

  • Moat Score: 7
  • GF Value™: $175.89 vs. price of $146.97 (16.4% below fair value)
  • GF Score™: 83/100 with 5 warning signs

No single metric tells the full story. See the RGEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Repligen Business Description

Other Exchanges RGN:Germany
Address 41 Seyon Street, Building 1, Suite 100, Waltham, MA, USA, 02453
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia Pacific contribute about 44%, 37%, and 19% of revenue, respectively.
83GF Score

Get the complete analysis for RGEN

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$146.97
Price
$175.89
GF Value